Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Assets (2020 - 2025)

Historic Return on Assets for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 1.3%.

  • Insight Molecular Diagnostics' Return on Assets fell 9200.0% to 1.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.3%, marking a year-over-year decrease of 9200.0%. This contributed to the annual value of 1.11% for FY2024, which is 10800.0% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Return on Assets stood at 1.3% for Q3 2025, which was down 9200.0% from 1.15% recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Return on Assets registered a high of 0.04% during Q4 2023, and its lowest value of 1.3% during Q3 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' median Return on Assets value was 0.41% (recorded in 2021), while the average stood at 0.53%.
  • In the last 5 years, Insight Molecular Diagnostics' Return on Assets surged by 4100bps in 2023 and then plummeted by -11200bps in 2024.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Return on Assets stood at 0.41% in 2021, then fell by -9bps to 0.45% in 2022, then surged by 92bps to 0.04% in 2023, then crashed by -2993bps to 1.16% in 2024, then decreased by -12bps to 1.3% in 2025.
  • Its Return on Assets stands at 1.3% for Q3 2025, versus 1.15% for Q2 2025 and 1.23% for Q1 2025.